Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX APPOINTS ROBERT B. PARKER, Ph.D. AS DIRECTOR, REGULATORY AFFAIRS & QUALITY SYSTEMS

Rochester, NY - Vaccinex, Inc. announced today that Dr. Robert B. Parker will join the company as Director, Regulatory Affairs & Quality Systems to support the company's advancing therapeutic antibody development programs.

Dr. Parker will be responsible for developing and implementing regulatory strategies and managing relationships with regulatory authorities. He will also be responsible for the on-going development and management of quality systems to ensure that drug development processes are in compliance with regulatory and biopharmaceutical industry standards.

Dr. Parker received a BS in Chemistry from Bates College in Lewiston, Maine and a Ph.D. in Pharmacology from Harvard University in Cambridge. He has over 35 years of experience in the pharmaceutical industry, sixteen of these years serving in senior management roles in drug Regulatory Affairs for major pharmaceutical companies such as Fisons and Celltech, and most recently as Senior Director, Regulatory Affairs for Genzyme Corporation, one of the world's leading biopharmaceutical companies. Dr. Parker also has extensive experience in both research and applied pharmacology, serving in various scientific, development, and senior management positions at Warner-Lambert/Parke-Davis, Pennwalt, Rorer Group and SmithKline Beecham.

Raymond E. Watkins, Vaccinex's Vice President of Operations, commented, "The combination of Bob's scientific training in applied pharmacology, his extensive drug development experience in all phases from pre-clinical through clinical stages, and, especially, his regulatory affairs leadership and compliance expertise make him an excellent addition to our organization. We are very pleased to have Bob as a new member of our product development team."

Vaccinex, Inc.

Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its proprietary ActivMAb® technology, Vaccinex can select fully human monoclonal antibodies against targets that would be difficult to address with other technologies. This technology can also be used to fully humanize mouse and other non-human antibodies. Vaccinex is developing a broad pipeline of antibody products and is currently engaged in six antibody development projects, four of which are entering pre-clinical development in 2006. The firm is headquartered in Rochester, NY and currently has 48 employees.

Contacts

Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105)
e-mail: rwatkins@vaccinex.com

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX APPOINTS ROBERT B. PARKER, Ph.D. AS DIRECTOR, REGULATORY AFFAIRS & QUALITY SYSTEMS Rochester, NY - Vaccinex, Inc. announced today that Dr. Robert B. Parker will join the company as Director, Regulatory Affairs & Quality Systems to support the company's advancing therapeutic antibody development programs. Dr. Parker will be responsible for developing and implementing regulatory strategies and managing relationships with regulatory authorities. He will also be responsible for the on-going development and management of quality systems to ensure that drug development processes are in compliance with regulatory and biopharmaceutical industry standards. Dr. Parker received a BS in Chemistry from Bates College in Lewiston, Maine and a Ph.D. in Pharmacology from Harvard University in Cambridge. He has over 35 years of experience in the pharmaceutical industry, sixteen of these years serving in senior management roles in drug Regulatory Affairs for major pharmaceutical companies such as Fisons and Celltech, and most recently as Senior Director, Regulatory Affairs for Genzyme Corporation, one of the world's leading biopharmaceutical companies. Dr. Parker also has extensive experience in both research and applied pharmacology, serving in various scientific, development, and senior management positions at Warner-Lambert/Parke-Davis, Pennwalt, Rorer Group and SmithKline Beecham. Raymond E. Watkins, Vaccinex's Vice President of Operations, commented, "The combination of Bob's scientific training in applied pharmacology, his extensive drug development experience in all phases from pre-clinical through clinical stages, and, especially, his regulatory affairs leadership and compliance expertise make him an excellent addition to our organization. We are very pleased to have Bob as a new member of our product development team." *Vaccinex, Inc. Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its proprietary ActivMAb® technology, Vaccinex can select fully human monoclonal antibodies against targets that would be difficult to address with other technologies. This technology can also be used to fully humanize mouse and other non-human antibodies. Vaccinex is developing a broad pipeline of antibody products and is currently engaged in six antibody development projects, four of which are entering pre-clinical development in 2006. The firm is headquartered in Rochester, NY and currently has 48 employees. Contacts* Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105) e-mail: rwatkins@vaccinex.com Back to News Archive Copyright © 2008 Vaccinex, Inc.